Weekly cisplatin administration concurrent with radiation therapy for locoregionally advanced nasopharyngeal carcinoma

Radiation therapy (RT) with concurrent and adjuvant chemotherapy has been a widely accepted treatment for patients with locoregionally advanced nasopharyngeal carcinoma (NPC). We administered 40 mg/m2 cisplatin (CDDP) weekly, concurrently with RT, to six consecutive patients with locoregionally adva...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2005-06, Vol.10 (3), p.201-203
Main Authors: Isobe, Koichi, Uno, Takashi, Aruga, Takashi, Kawakami, Hiroyuki, Ueno, Naoyuki, Hanazawa, Toyoyuki, Okamoto, Yoshitaka, Ito, Hisao
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Cancer
Carcinoma - drug therapy
Carcinoma - radiotherapy
Carcinoma - surgery
Chemotherapy
Cisplatin - administration & dosage
Cisplatin - adverse effects
Cisplatin - therapeutic use
Combined Modality Therapy
Disease-Free Survival
Effectiveness
Female
Humans
Male
Middle Aged
Nasopharyngeal Neoplasms - drug therapy
Nasopharyngeal Neoplasms - radiotherapy
Nasopharyngeal Neoplasms - surgery
Neck Dissection
Oncology
Platinum
Radiation
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Radiation therapy (RT) with concurrent and adjuvant chemotherapy has been a widely accepted treatment for patients with locoregionally advanced nasopharyngeal carcinoma (NPC). We administered 40 mg/m2 cisplatin (CDDP) weekly, concurrently with RT, to six consecutive patients with locoregionally advanced NPC to evaluate its toxicity and efficacy. The median number of courses of CDDP administration was 4.5 and the median radiation dose was 69.7 Gy. Grade 3 leukopenia was observed in three patients. All but one patient experienced grade 3 or 4 skin reactions, pharyngitis, or dysphagia. All but one patient achieved a complete response, and the remaining patient received radical neck dissection for persistent cervical lymphadenopathies, which contained no cancer cells. All six patients were disease-free at last contact, with a median follow up of 23.5 months. This regimen is well tolerated in patients with locoregionally advanced NPC.
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-004-0471-8